The technology centers on a B7-H3-specific monoclonal antibody, mAb 376.96, designed to target an epitope predominantly expressed on malignant cells. Detailed studies have validated its unique binding characteristics through both in vitro and in vivo experiments, confirming its high specificity and potential utility in cancer research, diagnostics, and therapeutics. Its development, built on extensive university research, reflects a sophisticated process that ensures the antibody’s precise affinity for the intended B7-H3 antigen, offering promise for more targeted interventions.